The MAGOH/hnRNPH1 axis promotes alternative splicing-derived soluble PD-L1 generation and attenuates PD-L1 blockade efficacy in gastric cancer

Abstract Despite the clinical success of PD-1 blockade, the therapeutic efficacy of PD-L1 blockade in gastric cancer (GC) remains limited. Soluble PD-L1 (sPD-L1) has been proposed to function as a decoy that sequesters anti-PD-L1 antibodies, potentially contributing to therapeutic resistance. Our previous study identified an exon 5/6-skipping PD-L1 splice variant, designated PD-L1-v1, as an important source of sPD-L1 in GC. We also found that MAGOH is highly expressed in GC and participates in alternative splicing regulation. Here, we demonstrate that PD-L1-v1 acts as a soluble decoy that limits PD-L1 blocker binding to membrane-bound PD-L1 on tumor cells, thereby impairing the antitumor efficacy of PD-L1 blockade. Mechanistically, MAGOH upregulates hnRNPH1 expression, primarily by enhancing its mRNA stability, and promotes hnRNPH1-dependent exon5/6 skipping of PD-L1 pre-mRNA, thereby facilitating PD-L1-v1 and sPD-L1 generation. These findings reveal a previously unrecognized mechanism of resistance to PD-L1 blockade and highlight the MAGOH/hnRNPH1 axis as a potential strategy for improving immunotherapy efficacy in GC.

Authors

Institutions

Publication Details

Journal
Cell Communication and Signaling
Published
2026-11-17
DOI
https://doi.org/10.1186/s12964-026-03379-w
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The MAGOH/hnRNPH1 axis promotes alternative splicing-derived soluble PD-L1 generation and attenuates PD-L1 blockade efficacy in gastric cancer

Donghui Zhou, Cheng Chen, Yuntong Li, Kecheng Jiang et al.
2 links
Cell Communication and Signaling
Cancer Immunotherapy and Biomarkers
article

The MAGOH/hnRNPH1 axis promotes alternative splicing-derived soluble PD-L1 generation and attenuates PD-L1 blockade efficacy in gastric cancer

Donghui Zhou, Cheng Chen, Yuntong Li, Kecheng Jiang, Shanshan Yu
article en

Abstract

Abstract Despite the clinical success of PD-1 blockade, the therapeutic efficacy of PD-L1 blockade in gastric cancer (GC) remains limited. Soluble PD-L1 (sPD-L1) has been proposed to function as a decoy that sequesters anti-PD-L1 antibodies, potentially contributing to therapeutic resistance. Our previous study identified an exon 5/6-skipping PD-L1 splice variant, designated PD-L1-v1, as an important source of sPD-L1 in GC. We also found that MAGOH is highly expressed in GC and participates in alternative splicing regulation. Here, we demonstrate that PD-L1-v1 acts as a soluble decoy that limits PD-L1 blocker binding to membrane-bound PD-L1 on tumor cells, thereby impairing the antitumor efficacy of PD-L1 blockade. Mechanistically, MAGOH upregulates hnRNPH1 expression, primarily by enhancing its mRNA stability, and promotes hnRNPH1-dependent exon5/6 skipping of PD-L1 pre-mRNA, thereby facilitating PD-L1-v1 and sPD-L1 generation. These findings reveal a previously unrecognized mechanism of resistance to PD-L1 blockade and highlight the MAGOH/hnRNPH1 axis as a potential strategy for improving immunotherapy efficacy in GC.

Cell Communication and Signaling
First Affiliated Hospital Zhejiang University (CN)
National Natural Science Foundation of China
Good health and well-being
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon